sulforaphane has been researched along with Non-alcoholic Fatty Liver Disease in 10 studies
sulforaphane: from Cardaria draba L.
sulforaphane : An isothiocyanate having a 4-(methylsulfinyl)butyl group attached to the nitrogen.
Non-alcoholic Fatty Liver Disease: Fatty liver finding without excessive ALCOHOL CONSUMPTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Most studies regarding the beneficial effect of sulforaphane (SFN) on non-alcoholic fatty liver disease (NAFLD) have focused on nuclear factor E2-related factor 2 (Nrf2)." | 8.12 | Sulforaphane ameliorates non-alcoholic fatty liver disease in mice by promoting FGF21/FGFR1 signaling pathway. ( Chen, W; He, Z; Ren, ZN; Wang, G; Wu, YK; Wu, YZ; Ye, XL; Zhai, QX; Zhang, H; Zhu, SL, 2022) |
| "Nonalcoholic fatty liver disease (NAFLD) is a major health concern." | 5.72 | Modulation of endoplasmic reticulum stress via sulforaphane-mediated AMPK upregulation against nonalcoholic fatty liver disease in rats. ( Mansour, SZ; Moawed, FSM; Moustafa, EM, 2022) |
| "Nonalcoholic fatty liver disease (NAFLD) is characterized by lipotoxicity and ectopic lipid deposition within hepatocytes." | 5.62 | Sulforaphane Attenuates Nonalcoholic Fatty Liver Disease by Inhibiting Hepatic Steatosis and Apoptosis. ( Li, J; Teng, W; Xie, S, 2021) |
| "Most studies regarding the beneficial effect of sulforaphane (SFN) on non-alcoholic fatty liver disease (NAFLD) have focused on nuclear factor E2-related factor 2 (Nrf2)." | 4.12 | Sulforaphane ameliorates non-alcoholic fatty liver disease in mice by promoting FGF21/FGFR1 signaling pathway. ( Chen, W; He, Z; Ren, ZN; Wang, G; Wu, YK; Wu, YZ; Ye, XL; Zhai, QX; Zhang, H; Zhu, SL, 2022) |
| " However, species, disease model, duration, SFN dosage as well as route of administration did not explain the heterogeneity among studies." | 2.72 | Sulforaphane ameliorates lipid profile in rodents: an updated systematic review and meta-analysis. ( Du, K; Fan, Y; Li, D, 2021) |
| "Non-alcoholic fatty liver disease (NAFLD) is a common clinicopathological condition, encompassing a range of conditions caused by lipid deposition within liver cells." | 2.55 | Antioxidant dietary approach in treatment of fatty liver: New insights and updates. ( Di Giacomo, M; Ferramosca, A; Zara, V, 2017) |
| "Nonalcoholic fatty liver disease (NAFLD) is a major health concern." | 1.72 | Modulation of endoplasmic reticulum stress via sulforaphane-mediated AMPK upregulation against nonalcoholic fatty liver disease in rats. ( Mansour, SZ; Moawed, FSM; Moustafa, EM, 2022) |
| "Sulforaphane (SFN) has been proven to be effective in alleviating many metabolic diseases, such as obesity and type 2 diabetes." | 1.72 | The protective effects of sulforaphane on high-fat diet-induced metabolic associated fatty liver disease in mice ( Hu, Q; Li, X; Lu, Y; Ma, S; Pang, X; Sun, J; Tian, S, 2022) |
| "Nonalcoholic fatty liver disease (NAFLD) is characterized by lipotoxicity and ectopic lipid deposition within hepatocytes." | 1.62 | Sulforaphane Attenuates Nonalcoholic Fatty Liver Disease by Inhibiting Hepatic Steatosis and Apoptosis. ( Li, J; Teng, W; Xie, S, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 7 (70.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, YK | 1 |
| Ren, ZN | 1 |
| Zhu, SL | 1 |
| Wu, YZ | 1 |
| Wang, G | 1 |
| Zhang, H | 1 |
| Chen, W | 1 |
| He, Z | 1 |
| Ye, XL | 1 |
| Zhai, QX | 1 |
| Li, J | 1 |
| Xie, S | 1 |
| Teng, W | 1 |
| Mansour, SZ | 1 |
| Moustafa, EM | 1 |
| Moawed, FSM | 1 |
| Ma, S | 3 |
| Pang, X | 3 |
| Tian, S | 4 |
| Sun, J | 3 |
| Hu, Q | 3 |
| Li, X | 4 |
| Lu, Y | 3 |
| Hong, L | 1 |
| Xu, Y | 2 |
| Wang, D | 1 |
| Zhang, Q | 1 |
| Xie, C | 1 |
| Wu, J | 1 |
| Zhong, C | 1 |
| Fu, J | 1 |
| Geng, S | 1 |
| Huang, X | 1 |
| Huangfu, B | 1 |
| Hu, Y | 1 |
| Xu, J | 1 |
| Gao, R | 1 |
| Huang, K | 1 |
| He, X | 1 |
| Du, K | 1 |
| Fan, Y | 1 |
| Li, D | 1 |
| Ferramosca, A | 1 |
| Di Giacomo, M | 1 |
| Zara, V | 1 |
| Lei, P | 1 |
| Teng, C | 1 |
| Huang, L | 1 |
| Liu, X | 1 |
| Wang, J | 1 |
| Zhang, Y | 1 |
| Li, B | 1 |
| Shan, Y | 1 |
| Yang, G | 1 |
| Lee, HE | 1 |
| Lee, JY | 1 |
2 reviews available for sulforaphane and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
Sulforaphane ameliorates lipid profile in rodents: an updated systematic review and meta-analysis.
Topics: Animals; Cardiovascular Diseases; Diabetes Mellitus; Isothiocyanates; Lipids; Mice; Non-alcoholic Fa | 2021 |
Antioxidant dietary approach in treatment of fatty liver: New insights and updates.
Topics: Animals; Anthocyanins; Antioxidants; Carotenoids; Catechin; Coumestrol; Curcumin; Energy Metabolism; | 2017 |
8 other studies available for sulforaphane and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
Sulforaphane ameliorates non-alcoholic fatty liver disease in mice by promoting FGF21/FGFR1 signaling pathway.
Topics: Animals; Diet, High-Fat; Fatty Acids, Nonesterified; Fibroblast Growth Factors; Isothiocyanates; Liv | 2022 |
Sulforaphane Attenuates Nonalcoholic Fatty Liver Disease by Inhibiting Hepatic Steatosis and Apoptosis.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Ceramides; Diet, High-Fat; Hep G2 Cells; Humans; | 2021 |
Modulation of endoplasmic reticulum stress via sulforaphane-mediated AMPK upregulation against nonalcoholic fatty liver disease in rats.
Topics: AMP-Activated Protein Kinases; Animals; Cytokines; Diet, High-Fat; Endoplasmic Reticulum Stress; Fat | 2022 |
The protective effects of sulforaphane on high-fat diet-induced metabolic associated fatty liver disease in mice
Topics: Animals; Bile Acids and Salts; Diabetes Mellitus, Type 2; Diet, High-Fat; Liver; Mice; Mice, Inbred | 2022 |
The protective effects of sulforaphane on high-fat diet-induced metabolic associated fatty liver disease in mice
Topics: Animals; Bile Acids and Salts; Diabetes Mellitus, Type 2; Diet, High-Fat; Liver; Mice; Mice, Inbred | 2022 |
The protective effects of sulforaphane on high-fat diet-induced metabolic associated fatty liver disease in mice
Topics: Animals; Bile Acids and Salts; Diabetes Mellitus, Type 2; Diet, High-Fat; Liver; Mice; Mice, Inbred | 2022 |
The protective effects of sulforaphane on high-fat diet-induced metabolic associated fatty liver disease in mice
Topics: Animals; Bile Acids and Salts; Diabetes Mellitus, Type 2; Diet, High-Fat; Liver; Mice; Mice, Inbred | 2022 |
Sulforaphane ameliorates bisphenol A-induced hepatic lipid accumulation by inhibiting endoplasmic reticulum stress.
Topics: Animals; Endoplasmic Reticulum Stress; Humans; Lipid Metabolism; Lipids; Liver; Mice; Non-alcoholic | 2023 |
Sulforaphane Ameliorates Nonalcoholic Fatty Liver Disease Induced by High-Fat and High-Fructose Diet via LPS/TLR4 in the Gut-Liver Axis.
Topics: Animals; Diet, High-Fat; Fructose; Inflammation; Lipopolysaccharides; Liver; Mice; Mice, Inbred C57B | 2023 |
Sulforaphane Improves Lipid Metabolism by Enhancing Mitochondrial Function and Biogenesis In Vivo and In Vitro.
Topics: Animals; Antioxidants; Cell Line; Diet, High-Fat; Gene Expression Regulation; Hepatocytes; Humans; I | 2019 |
A pharmacological inhibitor of NLRP3 inflammasome prevents non-alcoholic fatty liver disease in a mouse model induced by high fat diet.
Topics: Administration, Oral; Animals; Diet, High-Fat; Disease Models, Animal; Enzyme Inhibitors; Inflammaso | 2016 |